A drug suggested to deal with cholesterol was discovered to reduce coronavirus infection by 70% in laboratory research studies, with scientists requiring extra scientific trials among hospitalized COVID-19 patients.A team of researchers from the U.K. and Italy published findings in the Frontiers in Pharmacology journal Friday, finding that fenofibrate and fenofibric acid resulted in a considerable decrease in coronavirus infection in human cells when the drug was used in safe and approved concentrations, according to a news release published Friday.CLICK HERE TO FIND A COVID-19 VACCINE NEAR YOU”Our data shows that fenofibrate may have the potential to decrease the seriousness of COVID-19 signs and also infection spread,” Dr. Elisa Vicenzi of the San Raffaele Scientific Institute in Milan and co-author, said in the release. “Given that fenofibrate is an oral drug which is offered and really low-cost worldwide, together with its extensive history of clinical use and its good security profile, our data has global implications.”The group called for included scientific trials to check out use of the drug as a possible COVID-19 therapy, while keeping in mind studies are continuous at the University of Pennsylvania and Hebrew University of Jerusalem. Dr. Farhat Khanim of the University of Birmingham and matching study author, mentioned viral variants spurring rising infection rates and deaths in countries all over the world.”Whilst vaccine programs will hopefully decrease infection rates and virus spread in the longer term, there is still an urgent requirement to broaden our arsenal of drugs to deal with SARS-CoV-2-positive clients,” Khanim wrote.CLICK HERE TO GET THE FOX NEWS APPAnother author noted that considerable percentages of populations in many low-and-middle countries will likely go unvaccinated till 2022.”Whilst vaccination has actually been shown to minimize infection rates and severity of illness, we are as yet not sure of the strength and period of the action. Therapies are still urgently required to handle COVID-19 clients who develop signs or require hospitalisation,” Dr Alan Richardson, of Keele University in the UK, wrote in part.The drug was suggested to work by preventing the harmful overproduction of cytokines connected to coronavirus infection, and likewise deal with respiratory tract inflammation. Additional properties might prevent blood clotting seen in late-stage disease in numerous COVID-19 clients, study authors noted.
- Havent done your routine dusting? Experts say without cleaning, it could be life threatening – USA TODAY
- Thousands Protest Against France’s Coronavirus Health Pass As Stricter Rules Loom